Enteral feeding is the process of
ingesting food through the gastrointestinal (GI) tract. The gastrointestinal
tract is made up of the mouth, oesophagus, stomach, and intestines. Enteral
feeding can refer to nutrition delivered through the mouth or a tube directly
to the stomach or small intestine. The Enteral Feeding Formula market growth is
being driven primarily by the aging population. According to the United Nations
Department of Economic and Social Affairs 2019 report, it is estimated that by
2050, one in every six people worldwide will be over the age of 65 (16%), up
from one in every eleven in 2019. By 2050, one in every four people in Europe
and Northern America maybe 65 or older. For the first time in history, people
aged 65 and up outnumbered children under the age of five on a global scale in
2018. The number of people aged 80 and up is expected to triple, from 143
million in 2019 to approximately 426 million in 2050. As a result, all of the
aforementioned factors are expected to drive market growth. Enteral Feeding Formula Market is estimated at $5,351 million in 2021 growing at a CAGR of 6.5% over the forecast period 2022-2027
Growing demand for standard formula is owing to the availability of a wide range of standard formulas along with the increased need for low-cost nutritional formulations. Furthermore, there is a substantial demand for regular tube feeds among volume-sensitive patients or those on fluid restrictions. Renal failure, congestive heart failure, and Syndrome of Inappropriate Antidiuretic Hormone are examples of such conditions (SIADH). The disease-specific formula category is expected to grow owing to the rising prevalence of chronic diseases such as cancer, diabetes, and liver failure. In addition, in the approaching years, recent product improvements to cater to special nutritional requirements of various disorders are projected to drive demand. Standard tube feeds for individuals with Chronic Kidney Disease include Nestlé Health Science's NOVASOURCE RENAL and Abbott's SUPLENA (CKD).
North America holds a major share of the Enteral Feeding Formula Market. This is majorly attributed to the factors such as the rapidly aging population, the rising prevalence of preterm birth, and the increase in the number of chronic disease patients, North America is expected to dominate the enteral feeding formulas market. According to the Population Reference Bureau's Population Bulletin Aging in the United States, the population of Americans 65 and older is expected to nearly double from 52 million in 2018 to 95 million by 2060. Furthermore, according to WHO data, 15 million babies are born prematurely, and this figure is rising. As a result, all of the aforementioned factors are expected to drive market growth.
For more queries about "Enteral Feeding Formula Market" @ https://www.industryarc.com/support.php?id=508695
Global Enteral Feeding Formula Market Drivers
The Growing Cases Of Covid-19 And Hospital Admits Owing To It Is Driving The Market Growth
The COVID-19 outbreak is expected to have an impact on the enteral feeding formulas market, as good supportive care remains the cornerstone in managing critically ill patients with COVID-19 infection, and nutritional management of ICU admitted COVID-19 patients is an integral component of supportive measures. Early enteral nutrition (EN) should be started within 24-36 hours of admission to the ICU or within 12 hours of intubation and placement on mechanical ventilation, according to a study published in the Society of Critical Care Medicine and the American Society for Parenteral and Enteral Nutrition, 2020. The publication also advocated for enteral nutrition over parenteral nutrition.
Rising Incidence Of Inflammatory Bowel Disease And Malnutrition Is Boosting The Market Growth
Enteral nutrition is recommended for patients with chronic medical conditions to counteract a weakened immune system, which affects eating patterns and results in significant weight loss. According to the International Diabetes Federation (IDF), 463 million people aged 20 to 79 had diabetes in 2019, with the figure expected to rise to 700 million by 2045, representing a 51.2 percent increase between 2019 and 2045. The International Diabetes Federation (IDF) estimates that approximately 374 million people worldwide are at risk of developing type 2 diabetes driving the product demand. Enteral nutrition therapy, a nutritional treatment, is used to treat Inflammatory Bowel Disease (IBD) as well. In this treatment, food is replaced with a nutritionally balanced formula. These formulas give a well-balanced supply of all the energy, protein, vitamins, and minerals needed for healthy growth and nutrition. Dietary issues affect 23 percent of IBD patients who are followed up in an outpatient clinic and 85 percent of IBD patients who are hospitalised, according to the National Center for Biotechnology Information. Patients who are in the active phase and those who are in remission have different needs. Weight loss is noted in up to 75% of hospitalised patients with a CD exacerbation, and more than half of them have a negative nitrogen balance, all of which leads to the use of an enteral feeding formula product.
In October 2020, Nestle Health Science has launched China's first ready-to-drink protein-based total nutrition Foods for Special Medical Purposes (FSMPs) for malnourished people.
Major Players in this Market:
The major companies in the Global Enteral Feeding Formula Market include Abbott Laboratories, Nestle SA, Danone SA, Fresenius Kabi AG, B. Braun Melsungen AG, Reckitt Benckiser Group plc., Trovita Health Science, Global Health Product Inc., Meiji Holdings Co. Ltd., And Victus.
Over the years, companies have mainly focused on offering various enteral feeding formulas with different flavors that have high acceptance across the globe, thereby augmenting their respective positions in the market. Manufacturers in this market are involved in the production of more innovative Enteral Feeding Formulas. For instance, in September 2021, Abbott Introduced HarvestTM Products Made with Organic Fruits and Vegetables to Revital Mealtime for People with Feeding Tubes. It comes in a ready-to-use formula and resealable container for convenient on-the-go feedings. Rising number of new manufacturers producing these enteral feeding formulas are set to increase in the degree of competition are the major factors set to buoy the Global Enteral Feeding Formula market during 2022-2027.